Floatz logo

Copper

Refractory Malignant Solid Neoplasm

Mayo ClinicPhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
81/ 100

Competitive context

77 Active assets in the Refractory Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB
Nivolumab
CatalYm GmbH
Phase 2BB
AZD1775
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Copper is also rated in:

GlioblastomaDormant
B
Indicative ·
57 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
50 / 100
View asset →
GliomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →